Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.

ABSTRACT:

Background & aims

Sorafenib has been the standard of care for patients with advanced hepatocellular carcinoma and although immunotherapeutic approaches are now challenging this position, it retains an advantage in HCV-seropositive patients. We aimed to quantify the rate of tumour progression in patients receiving sorafenib and relate this figure to survival, both overall, and according to viral status.

Methods

Using serial data from an international clinical trial we applied a joint model to combine survival and progression over time in order to estimate the rate of tumour growth as assessed by tumour burden and serum alpha-fetoprotein, and the impact of treatment on liver function.

Results

High tumour burden at baseline was associated with an increased risk of death.

SUBMITTER: Kolamunnage-Dona R 

PROVIDER: S-EPMC9158473 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature